SN Bioscience Co. Ltd. announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer for SNB-101, a new drug for polymer nanoparticle anticancer under clinical trial.
SN Bioscience Co. Ltd. announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer for SNB-101, a new drug for polymer nanoparticle anticancer under clinical trial.